Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Giorgos Karianakis"'
Autor:
Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, Sotirios Papageorgiou
Publikováno v:
Blood. 140:9554-9556
Autor:
Theodoros P. Vassilakopoulos, Eleni Variami, Despina Mparmparousi, Elias Poulakidas, Nora-Athina Viniou, Ioannis Adamopoulos, Aikaterini Megalakaki, Maria Kotsopoulou, Sotirios G. Papageorgiou, Charalampos Pontikoglou, Christos K. Kontos, Menelaos Papoutselis, Giorgos Karianakis, Ioannis Kotsianidis, Helen A. Papadaki, Dimitrios Christoulas, Alexandra Kourakli, Michael Voulgarelis, Panagiotis T. Diamantopoulos, Elena E. Solomou, Panagiotis Zikos, Maria Papaioannou, Flora N. Kontopidou, Panagiotis Repousis, Anastasia Sioni, Vassiliki Pappa, Dimitrios Tsokanas, Despina Kaliontzi, Dimitrios Gogos, Maria Dimou, Eleftheria Hatzimichael, Argiris Symeonidis, Evdoxia Kamouza, Panayiotis Panayiotidis, Maria Dalekou, Athanasios Galanopoulos
Publikováno v:
Blood. 132:1822-1822
INTRODUCTION: The hypomethylating agents 5-azacitidine (5-AZA) and decitabine are recently considered the most preferable treatment option for patients with intermediate-2 and high-risk myelodysplastic syndromes (MDS), by International Prognostic Sco